Bioequivalence Molecule Types and Dosage Forms Tested

Why Molecule Type Shapes the Testing Path

Within the bioequivalence and bioavailability studies market, molecule type is the variable that most determines testing difficulty, more than dosage form alone, because a molecule's structural and manufacturing complexity dictates which analytical methods and reference-product comparisons a study can even use.

A standard small-molecule generic can often be characterised with well-established pharmacokinetic sampling and bioanalytical methods, while a complex generic or biosimilar frequently requires bespoke analytical development before a study protocol can even be finalised.

This is why CROs organise their bioanalytical capability investment around molecule complexity tiers rather than around dosage form categories, even though dosage form is what a sponsor typically searches for first.

A useful way to think about this ordering: two products in the same dosage form, say an oral solid tablet, can require entirely different testing paths if one is a standard small-molecule generic and the other is a complex generic with a novel delivery mechanism, even though both would appear in the same dosage-form search a sponsor might run first.

Sponsors developing a portfolio of related products often find that molecule complexity, not dosage form similarity, is what actually determines whether the same CRO relationship can cover the whole portfolio or whether different molecule types within that portfolio need to be routed to different specialist providers.

This portfolio-level view matters most for sponsors managing a filing calendar across several molecules at once, since discovering a capability gap for one molecule type mid-pipeline can force a sponsor to onboard a second provider under time pressure rather than as part of planned portfolio strategy.

A sponsor's regulatory affairs team therefore typically maps its entire pipeline against molecule complexity tiers early in annual planning, identifying which projects can stay with an existing provider relationship and which will need a specialist engaged well before that project's own timeline pressure begins.

Generic Pharmaceuticals and Complex Generics

Generic pharmaceuticals in the small-molecule category remain the largest single molecule type by study volume, reflecting the steady cadence of small-molecule patent expiries feeding new ANDA filings, and this volume concentrates among the client types most active in complex generics as much as among small-molecule generic filers specifically.

Complex generics, a category that includes products with intricate formulations, novel delivery systems, or complex active ingredients, require materially more advanced analytical capability than a standard small-molecule study, and sponsors developing them typically shortlist a narrower set of CROs with demonstrated complex-generic experience.

The gap between what a standard generic study and a complex generic study demands has widened as more first-wave complex generic approvals establish precedent for how regulators expect these products to be characterised.

A standard small-molecule generic study can often reuse well-established bioanalytical methods with only minor adaptation, while a complex generic frequently requires method development work before dosing even begins, adding weeks to a project timeline that a sponsor's internal planning has to account for from the outset.

Sponsors new to complex generic development sometimes underestimate this method-development lead time because their prior experience is built entirely on standard small-molecule filings, which is why an experienced CRO's early scoping conversation typically includes an explicit timeline discussion distinguishing method development from the study execution period itself.

A sponsor's first complex generic project is often the point at which its existing provider relationship is tested most directly, since a CRO that performed reliably on years of standard small-molecule work may still lack the specific analytical infrastructure a complex generic demands, forcing an otherwise satisfied sponsor to qualify a second provider.

This qualification gap has narrowed somewhat as demand for complex generic testing has grown, with several providers historically known for standard small-molecule work having since built out dedicated complex-generic analytical teams rather than continuing to refer that work elsewhere.

Sponsors weighing whether to stay with an existing provider or qualify a specialist for a first complex generic project typically request a detailed method-validation plan before deciding, since a vague assurance of capability carries more risk on a complex generic than it would on a routine small-molecule study.

The commercial terms attached to complex generic work also tend to differ from standard generic pricing, with providers more often quoting on a scope-of-work basis that accounts for method development time separately from the study execution fee, rather than the flatter per-study pricing common for standard small-molecule work.

A sponsor budgeting for a complex generic project for the first time should expect this scope-of-work structure to introduce more line-item variability into a proposal than a standard generic quote typically carries, which makes comparing two competing complex generic proposals a more detailed exercise than comparing standard generic pricing across providers.

Biosimilars and Comparability Studies

Biosimilars require comparability studies rather than conventional bioequivalence studies, a distinction that matters because a comparability study has to demonstrate similarity across a broader set of pharmacokinetic and, where applicable, pharmacodynamic parameters than a small-molecule bioequivalence comparison, connecting directly to the regulatory pathways biosimilar studies must satisfy.

This higher analytical bar is a direct consequence of biosimilars being large, structurally complex molecules rather than small molecules, and it is the same underlying driver behind this molecule type category's faster growth relative to standard small-molecule generics.

CROs building biosimilar comparability capability typically invest first in bioanalytical infrastructure and only later in the broader service-model breadth that a full-service small-molecule provider might already have, since the analytical bar has to be cleared before service breadth becomes relevant to a sponsor's shortlist.

Sponsors developing biosimilars also tend to engage a provider earlier in development than a small-molecule generic sponsor would, since comparability study design decisions made during early formulation work directly shape what data will be available when the pivotal comparability study is eventually run.

This earlier engagement pattern also changes the commercial relationship itself: a biosimilar sponsor is effectively selecting a long-term development partner rather than commissioning a single discrete project, which is why biosimilar-focused providers often structure pricing around a multi-phase development relationship rather than a single study fee.

Comparability studies for biosimilars are considerably more complex than a conventional small molecule bioequivalence study, since they typically require analytical characterisation alongside pharmacokinetic comparison, reflecting the larger, more structurally variable nature of biologic molecules relative to a small molecule generic.

Orally Inhaled and Nasal Drug Products

Orally inhaled and nasal drug products, commonly referred to as OINDPs, carry their own distinct testing considerations because the delivery mechanism itself, not just the active ingredient, affects how much drug reaches systemic circulation and how consistently it does so across administrations.

This molecule type category has historically been served by a smaller set of specialist CROs given the specialised inhalation and nasal deposition testing equipment involved, though that specialist base has been broadening as generic OINDP filings have increased.

Device-related variability, meaning differences introduced by the inhaler or nasal delivery device itself rather than by the drug substance, adds a layer of testing complexity that oral solid or injectable dosage forms do not carry, which is part of why this category has retained a narrower specialist provider base for longer than most other molecule types.

A sponsor developing a generic OINDP therefore has to evaluate a prospective provider's device-testing infrastructure as carefully as its pharmacokinetic capability, since a provider strong in one but not the other cannot deliver a complete OINDP study programme on its own.

Dosage Forms Tested

Oral solid dosage forms, covering tablets and capsules, remain the most commonly tested dosage form given their continued dominance of overall generic drug filings, and the analytical methods for this dosage form category are the most standardised across the industry.

Injectable formulations, topical formulations, transdermal patches, and ophthalmic or nasal formulations each carry testing considerations distinct from oral solid dosage, from sterility and stability handling for injectables to skin-permeation modelling for transdermal patches.

A sponsor developing a product in one of these less-standardised dosage form categories typically has a narrower field of qualified CROs to choose from than a sponsor developing a standard oral solid product, simply because fewer providers have built out the specific analytical infrastructure each dosage form requires.

Transdermal patch testing in particular requires skin-permeation modelling capability that most CROs built around oral solid or injectable work have not invested in, which keeps this dosage form's provider base concentrated among a small number of specialists even as generic transdermal filings have grown.

Injectable formulations carry their own sterility and stability handling demands throughout sample collection and storage, a logistical burden that adds cost and complexity to a study even when the underlying pharmacokinetic analysis itself is comparatively standard.

Injectable and transdermal dosage forms generally demand more specialised bioanalytical infrastructure than oral solid dosage testing, since absorption pathways and sampling requirements differ substantially across dosage form categories, a factor that shapes which CROs can realistically compete for a given study.